Last reviewed · How we verify
NCT06099912: DynaFiT
Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
trial in Multiple Myeloma in 131 participants. Currently enrolling.
8 September 2026
Quick facts
| Lead sponsor | FengYan Jin |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 131 |
| Start date | 8 September 2021 |
| Primary completion | 8 September 2026 |
| Estimated completion | 8 September 2029 |
| Sites | 1 location across China |
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Frailty — all drugs for Frailty →
Sponsor
FengYan Jin
Who can join
65 and older, any sex, with Multiple Myeloma or Frailty. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Frailty is dynamic and confers poor outcomes in elderly patients with newly diagnosed multiple myeloma (NDMM), mainly because of the high prevalence of treatment discontinuation due to intolerability. We designed a multi-center prospective study (DynaFiT) based on our real-life practice to evaluate the feasibility and benefits of a dynamic frailty-tailored therapy in elderly patients with different fitness/frailty statuses. Since Dara-based treatment have recently become the new standard regimens, in this amendment of the study, daratumumab added to VRd is recommended as induction therapy regimen.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study.
Zhang Y, Liang X, Xu W, Yi X, et al · · 2024 · cited 6× · PMID 38915117 · DOI 10.1186/s13045-024-01569-y -
Challenges in Multiple Myeloma Therapy in Older and Frail Patients.
Aureli A, Marziani B, Sconocchia T, Pasqualone G, et al · · 2025 · cited 2× · PMID 40149280 · DOI 10.3390/cancers17060944
Verify or expand the search:
- PubMed search for NCT06099912
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other FengYan Jin trials
Trials by the same sponsor.
- NCT07045168 — Risk-adapted Therapeutic Strategy in +1q NDMM · not yet recruiting
- NCT06252792 — Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma · recruiting
- NCT06946407 — Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Ne · NA · recruiting
- NCT06109233 — A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minima · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06099912 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by FengYan Jin
- Last refreshed: 12 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06099912.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing